More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Patients with treatment-naive neovascular age-related macular degeneration have positive outcomes with faricimab at 1 year, ...

The eye condition, which can induce the loss of central vision, could see effective treatment options pending FDA approval. Macular telangiectasia (MacTel) has long gone without a consensus treatment ...

Share on Pinterest The FDA has approved biosimilars for macular degeneration treatment. recep-bg/Getty Images The FDA approved two biosimilars for Eylea (aflibercept), a drug used to treat age-related ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

WAUSAU, Wis. (WSAW) - Geographic atrophy affects approximately one million people in the United States and is commonly associated with both dry and wet macular degeneration. Now a new treatment is ...

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

Dr. Miller answers the question: 'How Can Photodynamic Therapy Help AMD?' Aug. 24, 2009— -- Question: What is photodynamic therapy, when is it used to treat age-related macular degeneration (AMD) ...

PHILADELPHIA, Pennsylvania — Researchers saw a decrease in macular volume during the first year of fingolimod (Gilenya, Novartis) treatment among patients with multiple sclerosis (MS), according to a ...